Received Apr 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
lost his voice; he developed fatigue; cough; loss of appetite; This non-serious case was reported by a consumer via call center representative and described the occurrence of loss of voice in a elderly male patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. Co-suspect products included Influenza vaccine (Influenza vaccin) for prophylaxis and COVID-19 vaccine for prophylaxis. In OCT-2024, the patient received Arexvy, Influenza vaccin and COVID-19 vaccine. In OCT-2024, an unknown time after receiving Arexvy and Influenza vaccin, the patient experienced loss of voice (Verbatim: lost his voice), fatigue (Verbatim: he developed fatigue), cough (Verbatim: cough) and appetite lost (Verbatim: loss of appetite). The outcome of the loss of voice was not resolved and the outcome of the fatigue, cough and appetite lost were resolving. It was unknown if the reporter considered the loss of voice, fatigue, cough and appetite lost to be related to Arexvy. It was unknown if the company considered the loss of voice, fatigue, cough and appetite lost to be related to Arexvy. Additional Information: GSK Receipt Date : 17-APR-2025 Patient reported he received Arexvy vaccine on October of 2024. After received the vaccine, he developed fatigue, loss of appetite, cough, and losted his voice. Patient reported his voice had not recovered since he started experiencing the side effect. Patient reporeds that he received the Covid vaccine and a Flu vaccine the same day he received arexvy. It was unknown if the reporter considered the loss of voice, fatigue, cough and appetite lost to be related to Covid 19 vaccine and Flu vaccine.